eosinophil proliferation, are crucially involved in the local infiltration and activation of eosinophils (3) , whereas other Th2 cytokines IL-10 and IL-13 are important in inducing airway hyperreactivity and allergic inflammation (4) .
Th2 cytokines and certain chemokines play essential roles in the pathogenesis of allergic asthma (5) . IL-25 (IL-17E) is a novel Th2 proinflammatory cytokine belonging to a newly discovered member of the IL-17 cytokine family with IL-17 receptor homology 1 (Rh1) (6, 7) . IL-25 is secreted by CD4ϩ activated memory (CD45ϩROϩ) T cells (8) . Intranasal administration of IL-25 has been shown to induce the production of Th2 cytokines IL-4, IL-5, and IL-13 and the expression of chemokine eotaxin mRNA in the murine lung (9, 10) . The induction of IL-4, IL-5, and IL-13 resulted in Th2-like response marked by increased serum IgE, IgG 1 , and IgA concentrations; eosinophilia in blood, bronchoalveolar lavage, and lung tissue; and the development of pathologic changes including eosinophilic infiltrates, epithelial cell hyperplasia/hypertrophy, increased mucus secretion, and airway hyperreactivity in mice (9, 10) . Ikeda and colleagues (11) reported that bone marrow-derived mast cells could generate large amounts of IL-25 when the cells were challenged by IgE cross-linking, thereby indicating that mast cells may affect Th2 immunoresponse through the production of IL-25 (11) . Therefore, IL-25 plays an important role in provoking allergic inflammation, especially in IgE-dependent atopic diseases and eosinophil-mediated late phase allergic reactions (8) .
Transcription factor nuclear factor (NF)-B was found to involve in the expression of many inflammatory cytokines and adhesion molecules of eosinophils during allergic inflammation (12, 13) . IL-25 has also been shown to induce the activation of NF-B for the production chemokine IL-8 (6) . Our previous studies have indicated that the activation of NF-B and p38 mitogen-activated protein kinase (MAPK) plays a role in TNF-␣-activated signaling pathways regulating eotaxin release and the expression of adhesion molecules including intercellular adhesion molecule (ICAM)-1 in eosinophils (14) (15) (16) . However, the IL-25-mediated intracellular signal transduction for the activation of eosinophils has not been fully studied. In an attempt to elucidate the intracellular signaling mechanisms of IL-25-activated eosinophils in allergic inflammation, we investigated the induction of chemokines and cytokines and the modulation of intracellular NF-B and MAPK activities on the regulation of the release of chemokines and cytokines.
MATERIALS AND METHODS

Reagents
Recombinant human IL-25 was purchased from R&D Systems, Inc. (Minneapolis, MN). Cycloheximide and actinomycin D were purchased from Sigma-Aldrich Co. (St. Louis, MO). IB-␣ phosphorylation inhibitor BAY11-7082, JNK inhibitor SP600125, and p38 MAPK inhibitor SB203580 were purchased from Calbiochem Corp. (San Diego, CA). SB203580 was dissolved in water, whereas SP600125 and BAY11-7082 were dissolved in dimethyl sulfoxide (DMSO) (17) . In all studies, the concentration of DMSO was 0.1% (vol/vol).
Isolation of Human Blood Eosinophils from Buffy Coat and Eosinophil Culture
Fresh human buffy coat obtained from the Hong Kong Red Cross Blood Transfusion Service was diluted 1:2 with phosphate-buffered saline (PBS) at 4 ЊC and centrifuged using an isotonic Percoll solution (density 1.082 g/ml; Amersham and Pharmacia Biotech, Uppsala, Sweden) for 30 min at 1,000 ϫ g. The eosinophil-rich granulocyte fraction was collected and washed twice with cold PBS containing 2% fetal calf serum. The cells were then incubated with anti-CD16 magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) at 4 ЊC for 45 min, and CD16-positive neutrophils were depleted by passing through an LSϩ column (Miltenyi Biotec) within a magnetic field. With this preparation, the drop-through fraction contained eosinophils with a purity of at least 98% as assessed by Hemacolor rapid blood smear stain (E Merck Diagnostica, Darmstadt, Germany). The isolated eosinophils were cultured in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco) and 20 mM Hepes (Gibco).
Endotoxin-Free Solutions
Cell culture medium was purchased from Gibco, free of detectable lipopolysaccharide (LPS) (Ͻ 0.1 EU/ml). All other solutions were prepared using pyrogen-free water and sterile polypropylene plasticware. No solution contained detectable LPS, as determined by the Limulus amoebocyte lyase assay (sensitivity limit 12 pg/ml; Biowhittaker Inc., Walkersville, MD).
Assay of Viability
The % viability and necrosis of eosinophils were assessed by propidium iodide assay using a FACSCalibur flow cytometer and MTT tetrazolium colorimetric assay (Becton Dickinson Biosciences Corp., San Jose, CA).
Reverse Transcription-Polymerase Chain Reaction
Total RNA was extracted using Tri-Reagent (Molecular Research Center Inc., Cincinnati, OH).
Extracted RNA was reverse transcribed into first-strand complementary DNA using First-Strand cDNA Synthesis Kit (Amersham Biosciences Corp., Piscataway, NJ). Polymerase chain reaction (PCR) was performed in a reaction mixture containing 3 mM MgCl 2 , 200 M dNTPs, 1 unit of AmpliTaq Gold DNA polymerase (Applied Biosystems Ltd., Foster City, CA), 50 pmol of 5Ј and 3Ј primers (Invitrogen, Carlsbad, CA) in PCR reaction buffer (1 min each at 94 Њ, 56Њ, and 72 ЊC) for 30 cycles for ␤-actin, IL-6, IL-8, MCP-1, and MIP-1␣ after an initial 12 min of denaturation at 94 ЊC. All reverser transcription (RT)-PCR were performed in the linear range of the PCR reaction according to the preliminary experiments. PCR Primers were as the following: IL-8 sense, 5Ј-CTGTGTGAAGGTGCAGTTTTGCC-3Ј and antisense, 5Ј-CTCAG CCCTCTTCAAAAACTTCTCC-3Ј, yielding a 237-bp product (18); MCP-1 sense, 5Ј-AATGCCCCAGTCACCTGCTGTTAT-3Ј and antisense, 5Ј-GCAATTTCCCCAAGTCTCTGTATC-3Ј, yielding a 427-bp product (19) ; MIP-1␣ sense, 5Ј-GCTGACTACTTTGAGACGAGC-3Ј and antisense, 5Ј-CCAGTCCATAGAAGAGGTAGC-3Ј, yielding a 252-bp product; IL-6 sense, 5Ј-ATGAACTCCTTCTCCACAAGC-3Ј and antisense, 5Ј-TGGACTGCAGGAACTCCTT-3Ј, yielding a 610-bp product (18) ; ␤-actin sense, 5Ј-AGCGGGAAATCGTGCGTG-3Ј and antisense, 5Ј-CAGGGTACATGGTGGTGCC-3Ј, yielding a 300-bp product (16) . After the amplification reaction using PTC-200 DNA Engine (MJ Research, Inc., Boston, MA), PCR products were electrophoresed on 2% agarose gel in TAE buffer (pH 8.0) and stained with ethidium bromide. The electrophorectic bands were documented with Gene Genius Gel Documentation System (Syngene Inc, Cambridge, UK).
Protein Array Analysis of Chemokines and Cytokines in Culture of Eosinophils
The expression profile of 79 different cytokines in culture supernatant of eosinophils was assessed semiquantitatively using antibody-based RayBio human cytokine array V (RayBiotech Inc., Norcross, GA) (20) .
Quantitative Analysis of IL-8, MCP-1, MIP-1␣, and IL-6
IL-8 and MCP-1 concentrations in culture supernatant were measured by cytometric bead array (CBA) using a FACSCalibur flow cytometer (BD) (21, 22) , while IL-6 and MIP-1␣ were quantitated by ELISA kit from Diaclone Research Inc. (Besancon, France) and R&D Systems, respectively.
Flow Cytometry of Cell Surface Expression of ICAM-1
Eosinophils after preceding treatment were harvested and resuspended with cold PBS supplemented with 0.5% bovine serum albumin. After blocking with 2% human pooled serum for 20 min at 4 ЊC and washed with PBS supplemented with 0.5% bovine serum albumin, cells were incubated either with FITC-conjugated mouse anti-human ICAM-1 monoclonal antibody or fluorescein-conjugated mouse IgG 1 isotype for 30 min at 4 ЊC in darkness. After washing, cells were finally resuspended in 1% paraformaldehyde in 1ϫ PBS as fixative. Cell surface expression of ICAM-1 was then analyzed by flow cytometry in terms of mean fluorescence intensity.
Western Blot Analysis
Eosinophils were washed with ice-cold PBS and lysed in 0.2 ml lysis buffer (20 mM Tris-HCl, pH 8.0, 120 mM NaCl, 1% Triton X-100, 10 mM EDTA, 1 mM EGTA, 0.05% 2-mercaptoethanol, 1ϫ protease inhibitors). Cell debris was removed by centrifugation at 14,000 ϫ g for 15 min, and the supernatant was boiled in Laemmli sample buffer (Bio-Rad Laboratory, Hercules, CA) for 5 min. An equal amount of proteins was subjected to sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis before blotting onto a PVDF membrane (Amersham and Pharmacia Biotech). The membrane was blocked with 5% skimmed milk in Tris-buffered saline with 0.05% Tween 20, pH 7.6 for 1 h at room temperature, and probed with primary rabbit anti-human ␤-actin, anti-human phospho-p38 MAPK, anti-human phospho-JNK, anti-human phospho-IB-␣, anti-human total I-B antibody (Cell Signaling Technology Inc., Beverly, MA), or anti-human IL-25 receptor (IL-17-Rh1; R&D Systems) at 4 ЊC overnight. After washing, membrane was incubated with secondary donkey anti-rabbit antibody coupled to horseradish peroxidase (Amersham and Pharmacia Biotech) for 1 h at room temperature. Antibody-antigen complexes were then detected using ECL chemiluminescent detection system according to the manufacturer's instructions (Amersham and Pharmacia Biotech) (14) .
Electrophoretic Mobility Shift Assay
Eosinophils were harvested and washed, and nuclear proteins were extracted with NE-PER nuclear and cytoplasmic extraction reagents (Pierce Chemical Co, Rockford, IL) according to the manufacturer's instructions. Equal amounts of nuclear protein extracts were subjected to a test for NF-B protein/DNA binding using LightShift chemiluminescent EMSA kit (Pierce) with a biotin end-labeled NF-B oligonucleotide (5Ј-AGT TGA GGG GAC TTT CCC AGG C-3Ј) (Research Genetics Invitrogen Co., Huntsville, AL). Briefly, nuclear extracts were incubated with biotin end-labeled NF-B oligonucleotide for 20 min at room temperature to allow DNA/protein binding. The DNA/protein complexes were then resolved by a 6% native polyacrylamide gel electrophoresis and transferred to a Hybond-Nϩ membrane (Amersham and Pharmacia Biotech). The biotin end-labeled DNA was detected using a streptavidin-horseradish peroxidase conjugate and a chemiluminescent substrate (16) .
Statistical Analysis
All data were expressed as mean Ϯ SD. Differences between groups were assessed by one-way ANOVA analysis. A P value Ͻ 0.05 was considered significantly different. All analyses were performed using the Statistical Package for the Social Sciences (SPSS) statistical software for Windows, version 10.1.4 (SPSS Inc., Chicago, IL).
RESULTS
Protein Expression of IL-25 Receptor of Human Eosinophils
As shown in Figure 1 of IL-25 also expressed mRNA for IL-25 receptor using RT-PCR (data not shown). /well) were treated with or without IL-25 (50 ng/ml) for 36 h. Cell-free culture supernatant was then harvested and 79 different cytokines in culture supernatant were semiquantitated using antibody-based RayBio human cytokine array V. Positive and negative controls were designated at (1a, 1b,  1c, 1 d, 8j, 8k) and (1e, 1f, 1 g, 8i) , respectively. Triplicate experiments were performed with essentially identical results. ment. Therefore, the gene expression results confirmed the production of the corresponding chemokines and IL-6 in cytokine array. After culture for 36 h, cell viability was ‫ف‬ 65-70% for IL-25 (10-100 ng/ml)-treated eosinophils comparing to only 35% viability without IL-25 treatment at 36 h using propidium iodide assay with flow cytometry and trypan blue exclusion method. Therefore, IL-25 could actually enhance the viability of eosinophils at 36 h. Moreover, IL-25 could activate eosinophils to release IL-8, MIP-1␣, MCP-1, and IL-6 dose-dependently (0-100 ng/ml) at 8, 16, and 36 h (Figure 4) . Moreover, the release at early time was significantly lower than that at the later time points (all P Ͻ 0.05) ( Figure 4 ). As shown in Figure 5 , release of IL-8, MIP-1␣, MCP-1, and IL-6 induced by IL-25 could be suppressed by protein synthesis inhibitor cycloheximide and transcriptional inhibitor actinomycin D dose-dependently at 36 h incubation.
Effect of IL-25 on Release of Chemokines and IL-6 from Eosinophils In Vitro
Effect of IL-25 on the Cell Surface Expression of ICAM-1 on Eosinophils
As shown in Table 1 , IL-25 could upregulate the cell surface expression of ICAM-1 on eosinophils dose-dependently from 10-100 ng/ml.
Effect of IL-25 on the Activation of MAPK
Figures 6A and 6B show that IL-25 could activate eosinophils by rapidly inducing the phosphorylation of p38 MAPK and JNK within 1 h, thereby indicating the activation of p38 MAPK and JNK in eosinophils by IL-25. The specific p38 MAPK inhibitor /well) were cultured with or without IL-25 (10-100 ng/ml) for 8, 16 , and 36 h in a 24-well plate. Chemokines and cytokines released into the culture supernatant were determined by human chemokine CBA kit using flow cytometry and ELISA as described in MATERIALS AND METHODS. Results are expressed as the arithmetic mean Ϯ SD from three independent experiments. *P Ͻ 0.01, **P Ͻ 0.001 when compared with the control. SB203580 could inhibit the p38 MAPK activity by diminishing the enzymatic product phosphorylated ATF-2 ( Figure 6C ). ␤-Actin was used as control to ensure an equal protein amount was loaded at different time points ( Figure 6D ).
Effect of IL-25 on NF-B Activity of Eosinophils
As shown in Figure 7A , eosinophils without any treatment exhibited relatively low amount of phospho-IB-␣. IL-25-treated eosniophils could activate the NF-B activity by inducing the phosphorylation of IB-␣ at 1 h, while the total IB-␣ amount remained constant ( Figure 7B ). Figure 7C illustrates that untreated eosinophils showed a low shifted band, thereby indicating a basal activity of NF-B. Eosinophils treated with IL-25 (50 ng/ml) for 4 h were shown to activate NF-B for subsequent gene transcription, because there was a significant increase in band shift observed compared with the relative intensity of the shifted bands. Pretreatment with BAY (2.5 M) for 1 h was found to inhibit the band shift in eosinophils with or without IL-25 treatment. Competitive control at lane 6 using excessive unlabeled p50 NF-B binding DNA to totally suppress the IL-25-induced band shift confirmed the specificity of NF-B-DNA interaction. Eosinophils (5 ϫ 10 5 /well) were cultured with or without IL-25 (10-100 ng/ml) for 16 h in a 24-well plate. Cell surface expression of ICAM-1 was detected using flow cytometry. Results are expressed as the arithmetic mean Ϯ SD from three independent experiments. * P Ͻ 0.05, when compared with the control. Figure 8 shows that BAY11-7082 but not SP600125 or SB203580 could suppress the eosinophil viability in a dose-dependent manner at 36 h incubation. BAY11-7082, SP600125, and SB203580 on  IL-25-Induced Release of IL-8, MIP-1␣, MCP-1, and 
Effect of Different Inhibitors on the Viability of Eosinophils
Effect of
IL-6 from Eosinophils
As shown in Figure 9 , pretreatment of eosinophils with NF-B inhibitor BAY11-7082 (2.5 M), JNK inhibitor SP600125 (3 M), and p38 MAPK inhibitor SB203580 (10 M) for 1 h could significantly suppress the IL-25-induced release of IL-6, MIP-1␣, IL-8, and MCP-1 (all P Ͻ 0.05).
DISCUSSION
Although IL-25/IL-17E is structurally related to IL-17, the in vivo and in vitro biological activities of IL-25 are different from IL-17 and other IL-17-related family members such as IL-17B and IL-17C (9). Our previous clinical study has revealed the elevation of plasma IL-17 concentration in patients with allergic asthma (23) , and the median plasma concentration of IL-25 in patients with allergic asthma was 86 pg/ml, which was higher than that of control subjects (Ͻ 50 pg/ml). In animal studies, administration of IL-25 results in the induction of Th2 cytokines IL-4, IL-5, and IL-13, eosinophil chemokine eotaxin, eosinophilia, elevated serum IgE concentration, and the development of striking histologic changes in the lungs, mucus production, and airway hyperreactivity (9, 10) . Chemokines and cytokines have been shown to play important pathologic roles in allergic inflammation (21, 24) . In the present study, we first used cytokine protein array to screen for the induction of 79 diffferent cytokines and chemokines from eosinophils by IL-25. The results of the array analysis (Figure 2 ) in conjunction with those of CBA and ELISA (Figure 4) confirmed that IL-25 could selectively induce the significant in vitro release from eosinophils of inflammatory cytokine IL-6 for Th2 cells; CXC chemokine IL-8 for neutrophils; CC chemokine MCP-1 for monocytes, macrophages, eosinophils, and Th2 cells; and chemokine MIP-1␣ for monocytes and natural killer (NK) cells. In Figure 5 , both the protein synthesis inhibitor cycloheximide and transcriptional inhibitor actinomycin D could dose-dependently suppress the release of chemokines/cytokines upon IL-25 stimulation from eosinophils at 36 h. In conjunction with the upregulation of mRNA expression of chemokines/cyokines by IL-25 (Figure 3) , all the above results demonstrated that IL-25 actually induced newly synthesized chemokines and IL-6 rather than preformed chemokines and cytokines in eosinophils.
A recent study has shown that chemokines MIP-1␣ and IL-8 could be upregulated in body fluids or tissues 4-12 h after allergen challenge, and IL-6 was consistently increased after 18-24 h (25) . MCP-1 can trigger chemotaxis of eosinophils via the CCR2 receptor (26) . It has also been shown to provoke aggregation and release of histamines and prostaglandin D2 from mast cells for IgE-mediated hypersensitivity (27) , and its production is increased in allergic asthma (28) . Our present study of the induction of Th2 chemokine MCP-1 and Th2 cytokine IL-6 from eosinophils confirmed that Th2 cytokine IL-25 could provoke the Th2 response. The induction of IL-8 and MIP-1␣ can therefore mediate the infiltration of neutrophils, monocytes, and NK cells into the inflammatory sites at bronchial airway, thereby amplifying inflammatory responses during allergic asthma.
A recent study has shown that eosinophils may upregulate their chemokine receptors upon cytokine activation and use them during the progression of allergic inflammation for eosinophilic migration and activation (29) . Because eosinophils express CCR1 and CCR2 for MIP-1␣ and MCP-1, respectively, the modulation of chemokine receptors on eosinophils by IL-25 should also be investigated. Besides inducing eosinophilia, IL-25 can also cause neutrophil infiltration (10). Our results showed that IL-25 could induce the secretion of neutrophil chemokine IL-8 from eosinophils. Therefore, this study also provides further explanation of the mechanisms for IL-25-mediated neutrophil migration.
According to our present results, IL-25 could also upregulate the ICAM-1 cell surface expression dose-dependently (Table 1) , delay apoptosis of eosinophils, and may enhance the adhesion of eosinophils onto bronchial epithelial cells. Therefore, apart from the induction of chemokines, IL-25 could induce the eosinophilia in bronchoalveolar lavage and lung tissue by the increase of its adhesion onto epithelial cells and the subsequent transmigration into the inflammatory sites. Moreover, IL-25 could induce eotaxin release in lung tissue that can cause eosinophilia (10) . Together with the induction of Th2 and eosinophil chemokine MCP-1, Th2 cytokine IL-6, neutrophil chemokine IL-8, and NK and monocyte chemokine MIP-1, IL-25 should play an important role for the eosinophilia, Th2 immune response, and infiltration of inflammatory cells into inflammatory sites that are immunopathologic characteristics during allergic asthma. Our former study has shown that p38 MAPK and NF-B play crucial roles in the TNF-␣-mediated release of eotaxin from eosinophils (14) . The present intracellular mechanistic study indicates that IL-25 can activate JNK, p38, and NF-B activities (Figures 6 and 7) . We used inhibitors BAY11-7082, SP600125, and SB203580 to elucidate the intracellular signaling mechanisms regulating the induction of chemokines. Following previous publications (14, 16, 30, 17, 31) and the toxicity results in Figure 8 , we used the optimal concentration of BAY11-7082 (2.5 M), SP600125 (3 M), or SB203580 (10 M) with the highest inhibitory effect without any cell toxicity. The inhibition experiments demonstrated that the production of IL-8, MIP-1␣, MCP-1, and IL-6 was mediated by the intracellular JNK, p38 MAPK, and NF-B activities. It is because p38 MAPK, JNK, and NF-B are commonly signal transduction molecules by which the expression of cytokines and chemokines can be regulated in eosinophils (32) , it is reasonable that the above signaling molecules are commonly involved in IL-25-mediated release of IL-8, MIP-1␣, MCP-1, and IL-6 from eosinophils.
In conclusion, this is a first report on the activation of eosinophils for the release of chemokines and cytokines by IL-25. Our result suggest that IL-25-induced release of MCP-1, MIP-1␣, IL-8, and IL-6 from eosinophils is mediated by the combined activation of MAPK and NF-B pathways, thereby providing new clues for the elucidation of immunopathologic mechanisms of Th2-and eosinophil-mediated allergic inflammation in pulmonary disorders. Further investigations are required for other potential intracellular signaling pathways (e.g., Janus-activated kinase [JAK]-signal transducer and activator of transcription [STAT] ) for the regulation of the release of chemokines and cytokines. In view of recent advances in the application of p38 MAPK and NF-B inhibitors as potential anti-inflammatory agents in asthma (33, 34) , our study of IL-25 on eosinophil activation should provide new insights on the development of novel treatment for allergic disorders. /well) were pretreated with BAY11-7082 (2.5 M), SP600125 (3 M), or SB203580 (10 M) for 1 h followed by incubation with or without IL-25 (50 ng/ml) in the presence of inhibitors for further 36 h. Release of chemokines in culture supernatant was determined by human chemokine CBA kit or ELISA as described in MATERIALS AND METHODS. Results are expressed as the arithmetic mean Ϯ SD from three independent experiments. DMSO (0.1%) was used as the DMSO control. *P Ͻ 0.05, **P Ͻ 0.001 when compared with the IL-25 control.
